Aptevo Therapeutics INC

Aptevo Therapeutics announced a new solid tumor strategy and filed a patent for a Nectin-4 x PD-L1 dual-targeting backbone to enhance its oncology pipeline and expand partnering opportunities.

Aptevo Therapeutics has been awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to advance its trispecific antibody candidate, APVO451, for solid tumors.

Aptevo Therapeutics and Niowave have entered into a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making a strategic equity investment in Aptevo.

Aptevo Therapeutics announced its first-quarter 2026 business update, highlighting strong clinical data for mipletamig in frontline AML and a completed executive leadership transition.

Aptevo Therapeutics announced a leadership transition with Marvin L. White moving to Executive Chair and Jeff Lamothe becoming President and CEO, effective April 1, 2026.

Aptevo Therapeutics has entered into a $60 million equity line of credit with Yorkville Advisors Global, LP, extending its funding runway into 2029 to advance its multispecific portfolio.

Aptevo Therapeutics reported a net loss of $6.7 million for Q1 2026, with cash and cash equivalents decreasing to $14.5 million, while advancing its clinical pipeline.

Aptevo Therapeutics reported increased net losses for Q3 2025 but significantly strengthened its cash position through recent equity offerings, extending its cash runway into late 2026, while also announcing positive clinical data for mipletamig.

Aptevo Therapeutics reported continued losses and a going concern warning despite recent capital raises and positive clinical data for its lead cancer immunotherapy candidate.

Aptevo Therapeutics reports a net loss of $6.4 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while continuing clinical trials and seeking additional funding.

Aptevo Therapeutics reports a net loss of $17.8 million for the nine months ended September 30, 2024, and discusses ongoing clinical trials and recent financing activities.

Aptevo Therapeutics reported a net loss of $12.7 million for the first half of 2024 and highlighted substantial doubt about its ability to continue as a going concern, despite ongoing clinical development of its immuno-oncology candidates.

Aptevo Therapeutics, a clinical-stage biotech, reported positive clinical data for its lead cancer candidates mipletamig and ALG.APV-527, while addressing ongoing financial challenges and securing additional capital.

Aptevo Therapeutics Inc. releases its 10-K filing, detailing its financial results for fiscal year 2024 and providing updates on its clinical-stage immunotherapy candidates.

Aptevo Therapeutics, a clinical-stage biotech company, reported a net loss of $17.4 million for 2023, shifting from a net income of $8.0 million in 2022, while advancing its immunotherapy pipeline.

Aptevo Therapeutics Inc. Director Grady Grant III acquired 13,513 shares of common stock at $1.49 per share, increasing his direct beneficial ownership.

Bank of America entities report their beneficial ownership in Aptevo Therapeutics has fallen below 10%, ending Section 16 reporting obligations.

Aptevo Therapeutics Inc. Director Daniel Abdun-Nabi was granted 7,200 Restricted Stock Units, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc.'s SVP and CFO, Daphne Taylor, was granted 11,500 Restricted Stock Units, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc. director Grady Grant III was granted 7,200 Restricted Stock Units, vesting on the first anniversary of the grant date.

Aptevo Therapeutics Inc. granted 11,500 Restricted Stock Units to SVP and Chief Medical Officer Dirk Huebner, vesting fully on the first anniversary of the grant date.

Aptevo Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 21, 2026, to elect directors, ratify auditors, and approve an updated stock incentive plan.

Aptevo Therapeutics Inc. calls a special meeting to approve an amendment to its Certificate of Incorporation and a potential $60 million equity issuance under a Standby Equity Purchase Agreement.

Aptevo Therapeutics Inc. is seeking stockholder approval for a series of critical proposals at its upcoming 2025 Annual Meeting, including a reverse stock split to maintain Nasdaq listing, significant equity issuances for capital, and a new stock incentive plan, all aimed at bolstering its financial position and operational flexibility.

Aptevo Therapeutics is holding a special meeting to seek stockholder approval for a stock issuance and a reverse stock split to maintain its Nasdaq listing and secure funding.

Aptevo Therapeutics is holding a special meeting to seek stockholder approval for a stock issuance, warrant amendments, a reverse stock split, and adjournment authorization.

Aptevo Therapeutics is holding a special meeting of stockholders to vote on proposals including amending the company's certificate of incorporation and approving the issuance of common stock and warrants.

Aptevo Therapeutics entered a $60 million standby equity purchase agreement with YA II PN, LTD., registering shares for resale while advancing its cancer immunotherapy pipeline.

Aptevo Therapeutics Inc. filed an S-1 registration statement for the resale of up to 6.9 million common shares by YA II PN, LTD., part of a $25 million standby equity purchase agreement to fund its clinical-stage biotechnology pipeline.

Aptevo Therapeutics Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 8.25 million shares, enabling the company to potentially raise up to $25 million through a Standby Equity Purchase Agreement to fund its clinical-stage oncology pipeline.

Aptevo Therapeutics Inc. has filed a Rule 462(b) registration statement to register an additional $67,500 in securities, including common stock and warrants, for its ongoing public offering.

Aptevo Therapeutics Inc. has initiated a public offering of common stock and warrants to raise approximately $7.2 million, while simultaneously addressing significant financial challenges including a shareholders' deficit and Nasdaq listing non-compliance, despite reporting positive clinical trial results for its lead cancer candidates.

Aptevo Therapeutics is registering for resale up to 3,529,420 shares of common stock issuable upon the exercise of common stock purchase warrants.

CVI Investments and Heights Capital Management have disclosed an 8.2% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through warrants.

Bank of America Corp /DE/ has filed an amended Schedule 13G, reporting beneficial ownership of 86 shares, representing 0.0% of Aptevo Therapeutics Inc.'s common stock.

Bank of America Corporation has disclosed a 15.0% beneficial ownership stake in Aptevo Therapeutics Inc. common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 9.1% passive ownership stake in Aptevo Therapeutics Inc.

L1 Capital Global Opportunities Master Fund, Ltd. reported a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc. common stock through warrants.

CVI Investments and Heights Capital Management disclose a 9.9% beneficial ownership stake in Aptevo Therapeutics Inc. through warrants.